Alopecia Areata: A Complex Cytokine-Driven Disease
October 2020
in “
The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → Studysummary This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement. Our plain-language summary of this paper — not a Tressless recommendation.
The document from November 1, 2020, describes alopecia areata (AA) as an autoimmune disease characterized by hair loss, driven by complex immune mechanisms involving T-helper cells, particularly Th1/IFN-γ and Th2/IL-23. Jak inhibitors have shown clinical efficacy in AA, indicating the significance of these immune pathways. The disease is also associated with comorbidities like atopic and autoimmune thyroid diseases. Current treatments have limited efficacy, but new treatments, including Jak inhibitors, are promising, as evidenced by improvements in SALT scores in placebo-controlled trials. The document also notes that IL-15 and Th2-related biomarkers are upregulated in AA, with GWAS studies identifying Th2-related susceptibility loci. However, treatments targeting Th17 (IL-17A) and PDE4 showed limited efficacy in pilot trials with 11 and 20 patients, respectively. The document concludes that AA involves multiple immune axes and that targeted therapeutics are necessary to better understand and treat the disease.
